| __timestamp | Perrigo Company plc | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 675200000 | 5496000 |
| Thursday, January 1, 2015 | 771800000 | 9786000 |
| Friday, January 1, 2016 | 1205500000 | 6792000 |
| Sunday, January 1, 2017 | 1146500000 | 7313000 |
| Monday, January 1, 2018 | 1125800000 | 8382000 |
| Tuesday, January 1, 2019 | 1166100000 | 10803000 |
| Wednesday, January 1, 2020 | 1175500000 | 12944000 |
| Friday, January 1, 2021 | 1111400000 | 21967000 |
| Saturday, January 1, 2022 | 1210100000 | 32810000 |
| Sunday, January 1, 2023 | 1274600000 | 46542000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and Xenon Pharmaceuticals Inc. over the past decade. From 2014 to 2023, Perrigo's SG&A expenses have shown a steady increase, peaking at approximately 1.27 billion in 2023, marking a 90% rise from 2014. In contrast, Xenon Pharmaceuticals, a smaller player, has seen its SG&A expenses grow by over 740% during the same period, reaching nearly 46 million in 2023. This stark difference highlights the scale and operational strategies of these companies. While Perrigo's expenses reflect its expansive operations, Xenon's growth in SG&A suggests strategic investments in its burgeoning pipeline. This financial insight offers a window into the strategic priorities and market positioning of these pharmaceutical entities.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Xenon Pharmaceuticals Inc.
Intra-Cellular Therapies, Inc. vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Grifols, S.A. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Xenon Pharmaceuticals Inc.
Perrigo Company plc and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Perrigo Company plc or MannKind Corporation: Who Manages SG&A Costs Better?
Perrigo Company plc and Galapagos NV: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Xenon Pharmaceuticals Inc. and Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Arrowhead Pharmaceuticals, Inc.
Xenon Pharmaceuticals Inc. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Xenon Pharmaceuticals Inc. vs Travere Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Xenon Pharmaceuticals Inc. vs Evotec SE Trends and Insights